These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823 [TBL] [Abstract][Full Text] [Related]
84. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627 [TBL] [Abstract][Full Text] [Related]
85. Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: a qualitative modelling approach. Tiesjema B; Hermsen HP; van Eijkeren JC; Brandon EF Curr Gene Ther; 2010 Apr; 10(2):107-27. PubMed ID: 20222861 [TBL] [Abstract][Full Text] [Related]
86. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Plog MS; Guyre CA; Roberts BL; Goldberg M; St George JA; Perricone MA Hum Gene Ther; 2006 Jul; 17(7):705-16. PubMed ID: 16839270 [TBL] [Abstract][Full Text] [Related] [Previous] [New Search]